SCHEMBL14711499

SCHEMBL14711499

O=C(O)Cc1ccc(N2CCN(C(=O)CCCNC(=O)OCc3ccccc3)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.57
ME2 P23368 2/20 0.52
ME1 P48163 2/20 0.52
ME3 Q16798 2/20 0.52
MAPT P10636 5/20 0.51
NPSR1 Q6W5P4 2/20 0.51
LMNA P02545 1/20 0.51
TPSAB1 Q15661 1/20 0.49
TPSD1 Q9BZJ3 1/20 0.49
TPSG1 Q9NRR2 1/20 0.49
GRM5 P41594 3/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PREP P48147 2/20 0.47
SIGMAR1 Q99720 1/20 0.47
GAA P10253 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP2C19 P33261 1/20 0.47
GFER P55789 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14711402 0.87 ME2 (0.56) ME2ME1ME3MAPTLMNA
SCHEMBL14790781 0.86 ME2 (0.52) HTTME2ME1ME3MAPT
SCHEMBL18152298 0.84 HTT (0.65) HTTLMNATPSAB1TPSD1TPSG1
SCHEMBL14711250 0.83 GAA (0.49) ME2ME1ME3MAPTGRM5
SCHEMBL11266194 0.82 HTT (0.63) HTTLMNATPSAB1TPSD1TPSG1
SCHEMBL14295143 0.82 HTT (0.67) HTTLMNATPSAB1TPSD1TPSG1
SCHEMBL7685914 0.80 GAA (0.67) HTTMAPTLMNATPSAB1TPSD1
SCHEMBL11266633 0.80 GAA (0.67) HTTMAPTLMNATPSAB1TPSD1
SCHEMBL8642538 0.79 MEN1 (0.59) ME2ME1ME3MAPTNPSR1
SCHEMBL19210942 0.78 SMN1; SMN2 (0.56) HTTME2ME1ME3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 HTT 3090/4885ME2 1532/4885ME1 2440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.